Entecavir

CLINICAL USE

Treatment of chronic hepatitis B infection

DOSE IN NORMAL RENAL FUNCTION

500 mcg daily; 1000 mcg daily in lamivudine-refractory patients

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :295.3

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :13

%Excreted unchanged in urine &nbsp &nbsp : 75

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :Large

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :128–149

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

30–50 250 mcg daily; 500 mcg daily in lamivudine-refractory patients10–30 150 mcg daily; 300 mcg daily in lamivudine-refractory patients

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : 50 mcg daily; 100 mcg daily in lamivudine-refractory patients

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:0.3% dialysed. Dose as in GFR <10 mL/min

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :13% dialysed. Dose as in GFR <10 mL/min

HDF/high flux &nbsp :Dialysed. Dose as in GFR

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL/min

CAV/VVHD &nbsp &nbsp &nbsp:Likely to be dialysed. Dose as in GFR=10–30 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

Tags: post-by-auto-php